Biovail Corp

Type: Company

Name: Biovail Corp

Nationality: Canada

Web Address: http://www.biovail.com/

Fact Sheet: Fact Sheet for Biovail Corp

First reported May 24 2013 - Updated 16 hours ago - 1 reports

Bausch & Lomb Inc

Warburg Would Reap Threefold Return in Bausch Transaction

Warburg Pincus LLC would reap more than a threefold return on its $1.7 billion equity investment in Bausch & Lomb Inc. if talks to sell the eye-care company for $9 billion bear fruit, a person with knowledge of the matter said.The private-equity firm, ... [Published Bloomberg - May 24 2013]

Entities: Bausch & Lomb Inc, Warburg Pincus LLC, Valeant Pharmaceuticals International

First reported May 24 2013 - Updated 19 hours ago - 5 reports

Warburg Pincus LLC

Reports: B&L close to being acquired

Canada’s largest drugmaker is close to acquiring Bausch & Lomb Inc. in a roughly $9 billion deal, published reports state.Valeant Pharmaceuticals International Inc. is seeking to acquire the local eye-care company owned by private-equity firm Warburg ... [Published Rochester Business Journal - May 25 2013]

Entities: Bausch & Lomb Inc, Warburg Pincus LLC, Valeant Pharmaceuticals International, Brent Saunders, Acquisition

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Valeant Pharma near deal to acquire Bausch & Lomb -source

NEW YORK ( ) - Canada's Valeant Pharmaceuticals International Valeant shares reached their highest level since 2001 on the news and were up 10 percent at C$84.33 in Friday afternoon trading in Toronto. The move comes after Valeant The person that spoke ... [Published Yahoo! - May 24 2013]

Entities: Valeant Pharmaceuticals International, Bausch & Lomb Inc, Biovail Corp, Lisa Von Ahn, Warburg Pincus LLC

First reported May 22 2013 - Updated May 22 2013 - 2 reports

Bioniche holders Wells, Gubitz slam animal health sale

Today the group of concerned shareholders of . led by William (Bill) M. Wells, former chief executive officer of Biovail Corp., and Greg Gubitz, former general counsel and senior vice-president of corporate development at Biovail, questioned the company's ... [Published Stockwatch - May 22 2013]

Entities: Bioniche Life Sciences Inc, Animal Health, Biovail Corp, Private Equity, Management Team

First reported May 22 2013 - Updated May 22 2013 - 2 reports

Valeant opens international headquarters in Laval

. has officially inaugurated its new international headquarters in Laval. Valeant's chairman of the board and chief executive officer, J. Michael Pearson, presided over the ceremonies, accompanied by Valeant Canada's president and general manager, Jacques ... [Published Stockwatch - May 22 2013]

Entities: Valeant Pharmaceuticals International, Dermik Laboratories Inc, Quebec

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Biovail Corp

Bioniche dissidents add Macci as director nominee

Today the group of concerned shareholders of . led by William (Bill) M. Wells, former chief executive officer of Biovail Corp.; and Greg Gubitz, former general counsel and senior vice-president of corporate development at Biovail, will also nominate Anthony ... [Published Stockwatch - May 21 2013]

Entities: Bioniche Life Sciences Inc, Biovail Corp, Life Science, Global Operations, Biotechnology

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Valeant Pharmaceuticals International

Valeant Pharmaceuticals reports departure of Dr Laurence Paul

Specialist pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSX:VRX) revealed on Wednesday the resignation of Dr Laurence Paul from its board of directors due to expanded business, philanthropic and personal commitments. In ... [Published Individual.com - May 16 2013]

Entities: Valeant Pharmaceuticals International, Biovail Corp, Mergers & Acquisitions

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Valeant Pharmaceuticals director Paul resigns

.'s Dr. Laurence Paul has resigned from Valeant's board of directors due to expanded business, philanthropic and personal commitments. Dr. Paul was originally elected to Biovail Corp.'s board of directors in June, 2002, where he served in several capacities, ... [Published Stockwatch - May 16 2013]

Entities: Valeant Pharmaceuticals International, Biovail Corp, Resignation, J Michael Pearson, Mergers & Acquisitions

First reported May 14 2013 - Updated May 15 2013 - 2 reports

Bioniche shareholders led by former Biovail execs renew bid to oust board

TORONTO - A group of dissident shareholders of Bioniche Life Sciences Inc. (TSX:BNC) is launching a renewed bid to replace the company's board of directors.The shareholders, led by former Biovail Corp. executives William Wells and Greg Gubitz, filed Tuesday ... [Published StockHouse USA - May 15 2013]

Entities: Biovail Corp, Bioniche Life Sciences Inc, William Wells, Toronto stock exchange

First reported May 08 2013 - Updated May 09 2013 - 2 reports

Alexza Finds New U.S. Marketing Partner For Adasuve In Teva

A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant. ... [Published The Rose Sheet - May 08 2013]

Entities: United States, Biovail Corp, Valeant Pharmaceuticals International

First reported May 02 2013 - Updated May 02 2013 - 2 reports

UPDATE 2-Valeant raises profit forecast, hunts for deals

* First-quarter net loss $0.09/share vs $0.04 year earlier* Total revenue rises 25 percent* Sees 2013 cash EPS $5.55-$5.85 vs prior fcast $5.45-$5.75May 2 (Reuters) - Valeant Pharmaceuticals International Inc , Canada's biggest publicly traded drugmaker, ... [Published CNBC - May 02 2013]

Entities: Valeant Pharmaceuticals International, Actavis, Mergers & Acquisitions, Zovirax

First reported Apr 29 2013 - Updated Apr 30 2013 - 2 reports

Drug delivery technology sector to be worth $224.2 billion by 2017 (companiesandmarkets.com)

The drug delivery technology market has been forecast to reach a value of $224.2 billion by 2017, increasing from 2012's value of $142.5 billion.Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical ... [Published Presscontacts.com - Apr 29 2013]

Entities: Drug Delivery, Drugs, Geriatrics

Quotes

...niche market it can consolidate, similar to the way it built up its dermatology business," wrote Morningstar analyst David Krempa in a note. "Similar to dermatology, the ophthalmology market sees a high cash-pay component, so it faces minimal pricing pressure from governments and managed care."

Valeant Eyes Bausch & Lomb, Sending Shares Soaring 13% [Published Yahoo! Finance - May 25 2013]

...out of his hat," Gautam Dhingra, chief executive of High Pointe Capital Management, a small Valeant investor, said, referring to Valeant's CEO. "We are grateful for his magical acts but keeping a close eye on whether it is possible to keep pulling bigger and bigger rabbits out of the same hat."

UPDATE 3-Valeant near deal to acquire Bausch & Lomb -source [Published Reuters UK - May 24 2013]

...Pearson said after striking the EyeTech deal. "We will continue to look for future opportunities to acquire additional products and gain important critical mass in this specialty space."

Bausch & Lomb Nears $9 Billion Sale to Valeant [Published 4 Traders - May 24 2013]

"We are committed to neuroscience research and will be conducting further analyses of the data to inform the scientific community's efforts in finding new approaches to treat this debilitating disease" he added

Merck & Co drops Parkinson's prospect preladenant [Published PMLive - May 24 2013]

More Content

sort by: Date \| Relevance
Canadas Valeant in talks to buy Bausch & Lomb f... [Published domain-b - 19 hours ago]
Reports: B&L close to being acquired [Published Rochester Business Journal - May 25 2013]
Valeant Pharmaceuticals eyes Bausch & Lomb [Published Globe and Mail - May 25 2013]
Valeant Eyes Bausch & Lomb, Sending Shares Soar... [Published Yahoo! Finance - May 25 2013]
Warburg Would Reap Threefold Return in Bausch T... [Published Bloomberg - May 24 2013]
Valeant Near Deal to Acquire Bausch & Lomb: Source [Published PE Hub Blog - May 24 2013]
Is Valeant About To Make A Bold Bid For Bausch ... [Published MassDevice - May 24 2013]
UPDATE 3-Valeant near deal to acquire Bausch & ... [Published Reuters UK - May 24 2013]
Bausch & Lomb Nears $9 Billion Sale to Valeant [Published 4 Traders - May 24 2013]
Valeant Said Close to Buying Bausch & Lomb for ... [Published Washington Post - May 24 2013]
UPDATE 2-Valeant near deal to acquire Bausch & ... [Published Reuters - May 24 2013]
Valeant Pharma near deal to acquire Bausch & Lo... [Published Yahoo! - May 24 2013]
UPDATE 1-Valeant near deal to acquire Bausch & ... [Published CNBC - May 24 2013]
Merck & Co drops Parkinson's prospect preladenant [Published PMLive - May 24 2013]
Bioniche holders Wells, Gubitz slam animal heal... [Published Stockwatch - May 22 2013]
Concerned Shareholders of Bioniche Question Lat... [Published Canada NewsWire - May 22 2013]
Valeant opens international headquarters in Laval [Published Stockwatch - May 22 2013]
A first in Quebec: Valeant officially inaugurat... [Published Digital Journal - May 22 2013]
A first in Quebec: Valeant officially inaugurat... [Published Canada NewsWire - May 22 2013]
Bioniche dissidents add Macci as director nominee [Published Stockwatch - May 21 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire - May 17 2013]
Valeant Pharmaceuticals reports departure of Dr... [Published Individual.com - May 16 2013]
Valeant Pharmaceuticals director Paul resigns [Published Stockwatch - May 16 2013]
Valeant Pharmaceuticals Announces Resignation o... [Published Canada NewsWire - May 16 2013]
Valeant Pharmaceuticals Announces Resignation o... [Published Street Insider - May 16 2013]
Santarus Announces Exercise in Full of Option t... [Published TradingCharts.com - May 15 2013]
Bioniche shareholders led by former Biovail exe... [Published StockHouse USA - May 15 2013]
Bioniche shareholders led by former Biovail exe... [Published Brandon Sun - May 14 2013]
IntelGenx Technologies loses $500,000 in Q1 2013 [Published Stockwatch - May 14 2013]
IntelGenx Reports Q1, 2013 Results and Provides... [Published Stockwatch - May 14 2013]